Pulmonary Arterial Hypertension Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes key companies continuously working towards developing Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Pulmonary Arterial Hypertension Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. The pulmonary arteries are the blood vessels that carry blood from the right side of the heart through the lungs.

“Pulmonary Arterial Hypertension Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report:
• Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years. Pulmonary Arterial Hypertension Key players such as – Galectin Therapeutics, Celon Pharma, ATXA Therapeutics, Aerami Therapeutics, Cereno Scientific AB, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment
• Pulmonary Arterial Hypertension Emerging therapies such as – Belapectin, CPL409116, NTP42, AER-901, CS1, BIA 5-1058, Seralutinib, Ralinepag, Sotatercept, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.
• In July 2021, Acceleron Pharma initiated a Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
• The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH. The European Medicines Agency (EMA) has granted Priority Medicines(PRIME) designation to sotatercept for the treatment of Pulmonary Arterial Hypertension

Route of Administration
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment
• Pulmonary Arterial Hypertension Assessment by Product Type
• Pulmonary Arterial Hypertension By Stage and Product Type
• Pulmonary Arterial Hypertension Assessment by Route of Administration
• Pulmonary Arterial Hypertension By Stage and Route of Administration
• Pulmonary Arterial Hypertension Assessment by Molecule Type
• Pulmonary Arterial Hypertension by Stage and Molecule Type

DelveInsight’s Pulmonary Arterial Hypertension Report covers around products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:
Key companies developing therapies for Pulmonary Arterial Hypertension are – Galectin Therapeutics, Pfizer, Aerami Therapeutics, PhaseBio Pharmaceuticals, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others.

Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:
• Belapectin: Galectin Therapeutics
• CPL409116: Celon Pharma
• NTP42: ATXA Therapeutics
• AER-901: Aerami Therapeutics
• CS1: Cereno Scientific AB
• BIA 5-1058: Bial
• Seralutinib: Gossamer Bio
• Ralinepag: Arena Pharmaceuticals/United Therapeutics
• Sotatercept: Acceleron Pharma/Bristol Myers Squibb

Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment

Pulmonary Arterial Hypertension Pipeline Analysis:
The Pulmonary Arterial Hypertension pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
• Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies

Pulmonary Arterial Hypertension Pipeline Market Drivers
• Rise in the prevalence of Pulmonary Arterial Hypertension
• Rising government support for development of orphan drugs
• Robust Drug pipeline and the new product combinations

Pulmonary Arterial Hypertension Pipeline Market Barriers
• Side effects associated with the drugs
• High cost for Pulmonary Arterial Hypertension diagnosis and treatment

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
• Coverage: Global
• Key Pulmonary Arterial Hypertension Companies: Galectin Therapeutics, Celon Pharma, ATXA Therapeutics, Aerami Therapeutics, Cereno Scientific AB, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others
• Key Pulmonary Arterial Hypertension Therapies: Belapectin, CPL409116, NTP42, AER-901, CS1, BIA 5-1058, Seralutinib, Ralinepag, Sotatercept, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers

Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials

Table of Contents
1 Pulmonary Arterial Hypertension Report Introduction
2 Pulmonary Arterial Hypertension Executive Summary
3 Pulmonary Arterial Hypertension Overview
4 Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment
5 Pulmonary Arterial Hypertension Pipeline Therapeutics
6 Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)
7 Pulmonary Arterial Hypertension Mid Stage Products (Phase II)
8 Pulmonary Arterial Hypertension Early Stage Products (Phase I)
9 Pulmonary Arterial Hypertension Preclinical Stage Products
10 Pulmonary Arterial Hypertension Therapeutics Assessment
11 Pulmonary Arterial Hypertension Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Pulmonary Arterial Hypertension Key Companies
14 Pulmonary Arterial Hypertension Key Products
15 Pulmonary Arterial Hypertension Unmet Needs
16 Pulmonary Arterial Hypertension Market Drivers and Barriers
17 Pulmonary Arterial Hypertension Future Perspectives and Conclusion
18 Pulmonary Arterial Hypertension Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting